<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220818</url>
  </required_header>
  <id_info>
    <org_study_id>C03-043</org_study_id>
    <secondary_id>U1111-1114-0294</secondary_id>
    <nct_id>NCT00220818</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.</brief_title>
  <official_title>A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how quickly lansoprazole, once daily (QD),
      improves feeding in premature babies or babies less than 28 days of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, multicenter, pharmacokinetic/Pharmacodynamic and safety study in which infants
      will be randomized in an open-label fashion to receive 5 days of open-label treatment with
      lansoprazole pediatric suspension 1 mg/kg/day oral, or lansoprazole pediatric suspension 2
      mg/kg/day oral. On Dosing Days 1 and 5, blood samples will be obtained for drug assay. All
      subjects will be evaluated for inclusion in the pH monitoring portion of the study and will
      undergo pH monitoring, provided it is clinically indicated, at the discretion of the
      investigator. Intragastric pH monitoring (up to 24 hours) will be performed at Baseline, on
      Dosing Day 1 (or Day 2) and on Dosing Day 5 (or Day 6). Intraesophageal pH may be done in
      addition to intragastric pH at the discretion of the investigator. Subjects will be evaluated
      for safety, including a follow-up visit on Post-Dosing Day 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Analysis.</measure>
    <time_frame>Day 1 and 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Intragastric 24 hour pH (subset of 6 subjects)</measure>
    <time_frame>Day -1, 1 and 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastroesophageal Reflux Disease Symptom Assessment.</measure>
    <time_frame>Days 1-5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Lansoprazole 1.0 mg/kg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 2.0 mg/kg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.</description>
    <arm_group_label>Lansoprazole 1.0 mg/kg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.</description>
    <arm_group_label>Lansoprazole 2.0 mg/kg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized or outpatient male or female, term or post-term infants beyond the
             neonatal period (&gt;28 days) but less than 12 months of age, OR a preterm infant with a
             corrected age of at least 44 weeks but less than 12 months on Dosing Day 1.

          -  Clinically-evident Gastroesophageal Reflux Disease (feeding intolerance,
             regurgitation, wheezing or stridor with feedings)

          -  At least 7 days post-surgery without anticipated need for surgery during study

          -  No significant laboratory abnormalities

        Exclusion Criteria:

          -  Unstable, clinically significant disease or abnormality

          -  Congenital anomaly of the upper gastrointestinal tract

          -  Clinical evidence of acute sepsis

          -  Cystic fibrosis

          -  Medical condition requiring subject to not be fed by mouth/gastric tube
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>364 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Springer M, Atkinson S, North J, Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged &lt;1 year. Paediatr Drugs. 2008;10(4):255-63.</citation>
    <PMID>18590344</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs. 2008;10(4):265-74.</citation>
    <PMID>18590345</PMID>
  </results_reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. VP Clinical Sciences</name_title>
    <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
  </responsible_party>
  <keyword>Pediatric GERD</keyword>
  <keyword>Pediatric Gastroesophageal Reflux Disease</keyword>
  <keyword>lansoprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

